Loading...
Market
Will Gilead license Tubulis's ADC candidate by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Gilead Sciences or Tubulis
Story
Gilead and Tubulis Sign $20M ADC Agreement for Solid Tumors with $30M Opt-in Fee and $415M Milestones
Dec 3, 2024, 12:54 PM
Gilead Sciences Inc. has entered into an exclusive option and license agreement with Tubulis to develop an antibody-drug conjugate (ADC) candidate targeting select solid tumors. The agreement includes an upfront payment of $20 million, a $30 million opt-in fee, and potential milestone payments totaling up to $415 million, along with mid-single to low double-digit tiered royalties. The specific target of the ADC has not been disclosed, but it is indicated that it will be a Topoisomerase I (TopoI) ADC.
View original story
Similar markets
Yes • 50%
No • 50%
Less than $100B • 25%
$100B to $150B • 25%
$150B to $200B • 25%
More than $200B • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Roche • 25%
Pfizer • 25%
AstraZeneca • 25%
No new partnership • 25%
